A new type of COVID-19 test could help streamline the process of identifying COVID-19 cases, tracking SARS-CoV-2 variants and detecting co-infecting viruses.
Merck has launched its CRISPR inhibition (CRISPRi) whole-genome libraries and pools to complement its suite of genome-editing products and technologies.
Public health laboratories will aim to sequence the virus genomes of all positive COVID-19 tests in Australia and track COVID-19 using genomics across the country.
The TruePrime Single Cell Whole Genome Amplification Kit from 4basebio uses a novel method to achieve genome amplification from single or just a few cells.
Blood cancer patients at Melbourne's Epworth HealthCare and Peter MacCallum Cancer Centre now have access to circulating tumour DNA (ctDNA) genomic testing.
UK scientists have pioneered a new method for profiling the microbiome of preterm babies that can significantly speed up the identification of infections and indicate more effective treatments.
By combining single-cell analysis techniques with machine learning algorithms, researchers have developed a method to 'fingerprint' human cells.
scATAC-seq technology provides unprecedented opportunity to study the impact of epigenetic changes on development and disease.
Phase Genomics applies Hi-C and other proximity-ligation methods to enable chromosome-scale genome assembly and metagenomic deconvolution, as well as analysis of structural genomic variation and genome architecture.
Next-generation sequencing facility Micromon Genomics is the first Australian commercial user of the high-throughput genetic sequencer MGISEQ-2000.
Tecan has launched NGS DreamPrep, a fully automated approach to next-generation sequencing (NGS) library preparation for research use.
High-quality libraries are key to keeping next-generation sequencing maximising usable data.
Researchers from Newcastle University are investigating the genetic causes of male infertility — an often-overlooked condition about which very little is known.
When it comes to cancer treatment, tumour mutational burden has become increasingly utilised as a biomarker for immunotherapy response prediction.
The four new genes contribute to the devastating neurological disease, multiple sclerosis (MS).